I doubt if that will happen because I believe GIA is suicide.
Denner believes in fixing broken companies and then selling
them off. Now Denner obviously will do what he can to induce
sales, especially in Europe. But I still believe that a Eurocentric
BC (such as Bayer or AZN) would be best suited to optimize
uptake of Vazkepa in Europe and logically, I believe that AD
sees it that way as well. Remember, AZN could have bought
out AMRN well before Reduce-It results were out. Instead,
they acquired a public company that had an inferior drug candidate.
Stupid of AZN to have not bought AMRN at that time
Market Data 
Markets 
